Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin as Prophylaxis for Relapse in High-risk BCP ALL Post-Transplant
NCT07862946Phase 2Not yet recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Oct 2026
- Primary completion
- Oct 2030
- Countries
- 1
01
Overview
A Phase 2 trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL), sponsored by Fundación PETHEMA. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07862946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862946.